Lactating Ctcgrp nulls lose twice the normal bone mineral content due to fewer osteoblasts and more osteoclasts, whereas bone mass is fully restored after weaning in association with up-regulation of Wnt signaling and other novel genes

Endocrinology

Volumn 154, Issue 4, 2013, Pages 1400-1413

  Collins, Jillian N ^a   Kirby, Beth J ^a   Woodrow, Janine P ^a   Gagel, Robert F ^b   Rosen, Clifford J ^c   Sims, Natalie A ^d   Kovacs, Christopher S ^a,e  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Health Sciences Centre St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CTCGRP PROTEIN; DICKKOPF 1 PROTEIN; IGFBP2 PROTEIN; MEF2C PROTEIN; RNA; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MASS; BONE METABOLISM; BONE MINERAL; CONTROLLED STUDY; DOWN REGULATION; ENERGY CONSUMPTION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; LACTATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PREPREGNANCY CARE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETON; TIBIA; UPREGULATION; WEANING; WILD TYPE;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CALCIUM; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; LACTATION; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOCLASTS; TIBIA; UP-REGULATION; WEANING; WNT SIGNALING PATHWAY;

EID: 84875856540     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1931     Document Type: Article

References (93)

1. Kovacs CS. Calcium and bone metabolism disorders during pregnancy and lactation. Endocrinol Metab Clin N America. 2011;40: 795-826.
2. Kovacs CS, Kronenberg HM. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium and lactation. Endocr Rev. 1997;18:832-872.
3. Sowers M. Pregnancy and lactation as risk factors for subsequent bone loss and osteoporosis. J Bone Miner Res. 1996;11:1052-1060.
4. Polatti F, Capuzzo E, Viazzo F, Colleoni R, Klersy C. Bone mineral changes during and after lactation. Obstet Gynecol. 1999; 94:52-56.
5. Chantry CJ, Auinger P, Byrd RS. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr AdolescMed. 2004;158:650-656.
6. Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology. 2006;147:4010-4021.
7. Kovacs CS. Control of skeletal homeostasis during pregnancy and lactation-lessons from physiological models. In: Thakker RV, Whyte MP, Eisman JA, Igarashi T, eds. Genetics of Bone Biology and Skeletal Disease. San Diego: Academic Press/Elsevier; 2012: 221-240.
8. Teti A, Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone. 2009;44:11-16.
9. Qing H, Ardeshirpour L, Pajevic PD, et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012;27:1018-1029.
10. VanHouten JN, Dann P, Stewart AF, et al. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest. 2003;112:1429-1436.
11. VanHouten JN, Wysolmerski JJ. Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. Endocrinology. 2003; 144:5521-5529.
12. Collet P, Uebelhart D, Vico L, et al. Effects of 1-and 6-month spaceflight on bone mass and biochemistry in two humans. Bone. 1997;20:547-551.
13. Holick MF. Perspective on the impact of weightlessness on calcium and bone metabolism. Bone. 1998;22:105S-111S.
14. Tilton FE, Degioanni JJ, Schneider VS. Long-term follow-up of Skylab bone demineralization. Aviat Space Environ Med. 1980;51: 1209-1213.
15. Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab. 1995;80:2859-2865.
16. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
17. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15:993-1000.
18. Reid IR. Menopause. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. Washington, DC: ASBMR Press; 2003:86-89.
19. Gallagher JC. Effect of estrogen on bone. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 5th ed. Washington, DC: ASBMR Press; 2003:327-330.
20. Miller SC, Bowman BM. Rapid inactivation and apoptosis of osteoclasts in the maternal skeleton during the bone remodeling reversal at the end of lactation. Anat Rec (Hoboken). 2007;290: 65-73.
21. Ardeshirpour L, Dann P, Adams DJ, et al. Weaning triggers a decrease in receptor activator of nuclear factor-κB ligand expression, widespread osteoclast apoptosis, and rapid recovery of bone mass after lactation in mice. Endocrinology. 2007;148:3875-3886.
22. Miller SC, Anderson BL, Bowman BM. Weaning initiates a rapid and powerful anabolic phase in the rat maternal skeleton. Biol Reprod. 2005;73:156-162.
23. Qing H, Bonewald LF. Osteocyte remodeling of the perilacunar and pericanalicular matrix. Int J Oral Sci. 2009;1:59-65.
24. Kirby BJ, Ardeshirpour L, Woodrow JP, et al. Skeletal recovery after weaning does not require PTHrP. J Bone Miner Res. 2011;26:1242-1251.
25. Liu XS, Ardeshirpour L, VanHouten JN, Shane E, Wysolmerski JJ. Site-specific changes in bone microarchitecture, mineralization, and stiffness during lactation and after weaning in mice. J Bone Miner Res. 2012;27:865-875.
26. Fudge NJ, Kovacs CS. Pregnancy up-regulates intestinal calcium absorption and skeletal mineralization independently of the vitamin D receptor. Endocrinology. 2010;151:886-895.
27. Kirby BJ, Karaplis AC, Kovacs CS. Calcitriol increases during pregnancy and bone formation upregulates post-lactation without parathyroid hormone. Bone. 2011;48:S101-S102.
28. Hoff AO, Catala-Lehnen P, Thomas PM, et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest. 2002;110:1849-1857.
29. Sharpe CJ, Fudge NJ, Kovacs CS. A rapid 35% flux in bone mass occurs during pregnancy and lactation cycles in mice [abstract]. International Bone and Mineral Society Meeting, Osaka, Japan, June 3-7, 2003. Bone. 2003;32 (suppl):S227.
30. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
31. Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ. Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab. 2006;290:E456-E462.
32. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
33. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK. Localpooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics. 2003;19: 1945-1951.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological). 1995;57:289-300.
35. Simmonds CS, Karsenty G, Karaplis AC, Kovacs CS. Parathyroid hormone regulates fetal-placental mineral homeostasis. J Bone Miner Res. 2010;25:594-605.
36. Kovacs CS, Woodland ML, Fudge NJ, Friel JK. The vitamin D receptor is not required for fetal mineral homeostasis or for the regulation of placental calcium transfer. Am J Physiol Endocrinol Metab. 2005;289:E133-E144.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-ΔΔC(T)] Method. Methods. 2001;25:402-408.
38. Montero A, Okada Y, Tomita M, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest. 2000;105:1085-1093.
39. Garner SC, Pi M, Tu Q, Quarles LD. Rickets in cation-sensing receptor-deficient mice: an unexpected skeletal phenotype. Endocrinology. 2001;142:3996-4005.
40. Kirby BJ, Karaplis AC, Kovacs CS. 2010 Stimulation of bone formation and mineralization post-weaning without parathyroid hormone. J Bone Miner Res 2010(suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/ AbstractDetail.aspx?aid-59f8e1fc-623d-4826-a568-29e32e11f525. Accessed February 19, 2013.
41. Breier BH, Milsom SR, Blum WF, Schwander J, Gallaher BW, Gluckman PD. Insulin-like growth factors and their binding proteins in plasma and milk after growth hormone-stimulated galactopoiesis in normally lactating women. Acta Endocrinol (Copenh). 1993;129:427-435.
42. Vicini JL, Buonomo FC, Veenhuizen JJ, Miller MA, Clemmons DR, Collier RJ. Nutrient balance and stage of lactation affect responses of insulin, insulin-like growth factors I and II, and insulin-like growth factor-binding protein 2 to somatotropin administration in dairy cows. J Nutr. 1991;121:1656-1664.
43. Colaianni G, Sun L, Di Benedetto A, et al. Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem. 2012;287:29159-29167.
44. Gooi JH, Pompolo S, Karsdal MA, et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 2010;46:1486-1497.
45. Villa I, Melzi R, Pagani F, Ravasi F, Rubinacci A, Guidobono F. Effects of calcitonin gene-related peptide and amylin on human osteoblast-like cells proliferation. Eur J Pharmacol. 2000;409:273-278.
46. Cornish J, Callon KE, Lin CQ, et al. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J Bone Miner Res. 1999;14:1302-1309.
47. Wang YS, Wang YH, Zhao GQ, Li YB. Osteogenic potential of human calcitonin gene-related peptide alpha gene-modified bone marrow mesenchymal stem cells. Chin Med J (Engl). 2011;124: 3976-3981.
48. HanN, Jiang BG, Wang TB, Zhang PX, Kou YH, Zhang DY. [Effect of calcitonin gene-related peptide onRUNX2expression in primary rat osteoblasts]. J Peking Univ Health Sci. 2011;43:652-656.
49. Wang L, Shi X, Zhao R, et al. Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-κB activation, osteoclastogenesis and bone resorption. Bone. 2010;46:1369-1379.
50. Schinke T, Liese S, Priemel M, et al. Decreased bone formation and osteopenia in mice lacking α-calcitonin gene-related peptide. J Bone Miner Res. 2004;19:2049-2056.
51. Winkler IG, Sims NA, Pettit AR, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood. 2010;116:4815-4828.
52. Etienne W, Meyer MH, Peppers J, Meyer RA Jr. Comparison of mRNAgene expression by RT-PCR andDNAmicroarray. Biotechniques. 2004;36:618-620, 622, 624-616.
53. Morey JS, Ryan JC, Van Dolah FM. Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proc Online. 2006;8:175-193.
54. Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M. Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res. 2012;27:360-373.
55. Bonewald LF. Mef2c does more than regulate Sost in osteocytes: distinct gender effects. IBMS Bone Key. 2012;9.
56. Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148:2635-2643.
57. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012; 33(5):747-783.
58. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-543.
59. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589.
60. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-869.
61. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010;25:178-189.
62. MorvanF, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934-945.
63. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-6276.
64. MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV. Bone mass is inversely proportional to Dkk1 levels in mice. Bone. 2007;41:331-339.
65. Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 2010;339:189-195.
66. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2012;13:27-38.
67. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7:447-456.
68. Boskey AL, Gelb BD, Pourmand E, et al. Ablation of cathepsin K activity in the young mouse causes hypermineralization of long bone and growth plates. Calcif Tissue Int. 2009;84:229-239.
69. Fujita Y, Nakata K, Yasui N, et al. Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization. J Clin Endocrinol Metab. 2000;85:425-431.
70. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 1998;95:13453-13458.
71. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14:1654-1663.
72. Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep. 2012;10:73-79.
73. Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res. 2001;16:1444-1452.
74. DeMambro VE, Maile L, Wai C, et al. Insulin-like growth factorbinding protein-2 is required for osteoclast differentiation. J Bone Miner Res. 2012;27:390-400.
75. Redd EH, Miller SC, Jee WS. Changes in endochondral bone elongation rates during pregnancy and lactation in rats. Calcif Tissue Int. 1984;36:697-701.
76. Dawood MY, Khan-Dawood FS, Wahi RS, Fuchs F. Oxytocin release and plasma anterior pituitary and gonadal hormones inwomen during lactation. J Clin Endocrinol Metab. 1981;52:678-683.
77. Colaianni G, Di Benedetto A, Zhu LL, et al. Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochem Biophys Res Commun. 2011;411:512-515.
78. Colucci S, Colaianni G, Mori G, Grano M, Zallone A. Human osteoclasts express oxytocin receptor. Biochem Biophys Res Commun. 2002;297:442-445.
79. Tamma R, Colaianni G, Zhu LL, et al. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci USA. 2009;106:7149-7154.
80. Liu X, Shimono K, Zhu LL, et al. Oxytocin deficiency impairs maternal skeletal remodeling. Biochem Biophys Res Commun. 2009; 388:161-166.
81. Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR, Matzuk MM. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc Natl Acad Sci USA. 1996;93: 11699-11704.
82. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-468.
83. Nervina JM, Magyar CE, Pirih FQ, Tetradis S. PGC-1α is induced by parathyroid hormone and coactivates Nurr1-mediated promoter activity in osteoblasts. Bone. 2006;39:1018-1025.
84. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT. Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA. 2009;106: 20405-20410.
85. Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun. 1997;235:79-82.
86. Xiao XQ, Grove KL, Grayson BE, Smith MS. Inhibition of uncoupling protein expression during lactation: role of leptin. Endocrinology. 2004;145:830-838.
87. Park SJ, Gadi J, Cho KW, et al. The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin beta1 expression. Bone. 2011;49:428-438.
88. Iida K, Koseki H, Kakinuma H, et al. Essential roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis. Development. 1997;124:4627-4638.
89. Kim SH, Cho KW, Choi HS, et al. The forkhead transcription factor Foxc2 stimulates osteoblast differentiation. Biochem Biophys Res Commun. 2009;386:532-536.
90. Zhou Y, Rui L. Major urinary protein regulation of chemical communication and nutrient metabolism. Vitam Horm. 2010;83:151-163.
91. Beynon RJ, Hurst JL. Multiple roles of major urinary proteins in the house mouse, Mus domesticus. Biochem Soc Trans. 2003;31:142-146.
92. Sang M, Wang L, Ding C, et al. Melanoma-associated antigen genes-an update. Cancer Lett. 2011;302:85-90.
93. Ohman Forslund K, Nordqvist K. The melanoma antigen genes-any clues to their functions in normal tissues? Exp Cell Res. 2001; 265:185-194.